Advertisement

The European Journal of Health Economics

, Volume 17, Supplement 1, pp 109–117 | Cite as

Social/economic costs and health-related quality of life in patients with scleroderma in Europe

  • Julio López-BastidaEmail author
  • Renata Linertová
  • Juan Oliva-Moreno
  • Pedro Serrano-Aguilar
  • Manuel Posada-de-la-Paz
  • Panos Kanavos
  • Domenica Taruscio
  • Arrigo Schieppati
  • Georgi Iskrov
  • Márta Péntek
  • Claudia Delgado
  • Johann Mathias von der Schulenburg
  • Ulf Persson
  • Karine Chevreul
  • Giovanni Fattore
  • The BURQOL-RD Research Network
Original Paper

Abstract

Objective

The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with systemic sclerosis (SSc; scleroderma) in Europe.

Methods

We conducted a cross-sectional study of patients with SSc (involving both localised and systemic sclerosis) from Germany, Italy, Spain, France, the UK, Hungary and Sweden. Data on demographic characteristics, healthcare resource utilisation, informal care, labour productivity losses and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire.

Results

A total of 589 patients completed the questionnaire. The rate of patients with localised scleroderma, limited cutan and diffuse cutan SSc were 28, 68 and 4 %, respectively. Average annual costs varied from country to country and ranged from € 4607 to € 30,797 (reference year: 2012). Estimated direct healthcare costs ranged from € 1413 to € 17,300; direct non-healthcare costs ranged from € 1875 to € 4684 and labour productivity losses ranged from € 1701 to € 14,444. The mean EQ-5D index score for adult SSc patients varied from 0.49 to 0.75 and the mean EQ-5D visual analogue scale score was between 58.72 and 65.86.

Conclusion

The main strengths of this study lie in our bottom-up approach to costing and our evaluation of SSs patients from a broad societal perspective. This type of analysis is very unusual in the international literature on rare diseases in comparison with other illnesses. We concluded that SSc patients incur considerable societal costs and experience substantial deterioration in HRQOL.

Keywords

Scleroderma Systemic sclerosis Localised scleroderma Cost of illness Health-related quality of life Economic burden 

Notes

Acknowledgments

The authors wish to thank: National Alliance of People with Rare Diseases (NAPRD), Bulgaria; Alliance Maladies Rares, France; ACHSE, Germany; Hungarian Federation of People with Rare and Congenital Diseases (RIROSZ), Hungary; Federazione Italiana Malattie Rare (UNIAMO), Italy; the Consulta Nazionale delle Malattie Rare, Italy; Rare Diseases Sweden; Federación Española de Efermedades Raras (FEDER), Spain; Rare Disease UK and Rare Diseases Europe (EURORDIS); FESCA (Federation of European Scleroderma Associations); Association des Sclérodermiques de France; Sklerodermie Selbsthilfe e.V., Germany; Országos Scleroderma Közhasznú Egyesület, Hungary; AILS—Associazione italiana lotta alla Sclerodermia and As.MA.RA—Associazione malattia rara Sclerodermia ed altre malattie rare “Elisabetta Giuffre”, Italy; Reumatikerförbundet, Sweden; Asociación Española de Esclerodermia and Asociación de Esclerodermia de Castellón, Spain; Raynaud’s and Scleroderma Association and Scleroderma Society, UK. Juan Oliva-Moreno and Julio López-Bastida are also grateful for the support of the project ECO2013-48,217-C2-2-R, “Impacto económico, sanitario y social de las enfermedades y los problemas de salud: información y herramientas para la evaluación de políticas públicas—Socioeconomic and healthcare impact of health problems: information and tools for the evaluation of public policies”.

Compliance with ethical standards

Funding

Supported by the Social/Economic Burden and Health-Related Quality of Life in Patients with Rare Diseases in Europe Project, which received funding from the European Union within the framework of the Health Programme [grant A101205]. The Executive Agency of the European Union is not responsible for any use that may be made of the information contained herein.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

10198_2016_789_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 kb)
10198_2016_789_MOESM2_ESM.doc (41 kb)
Supplementary material 2 (DOC 41 kb)

References

  1. 1.
    Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., Sibilia, J.: Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37, 223–235 (2008)CrossRefPubMedGoogle Scholar
  2. 2.
    Czirjak, L., Kiss, C.G., Lovei, C., Suto, G., Varju, C., Fuzesi, Z.: Survey of Raynaud’s phenomenon and systemic sclerosis based on a representative study of 10,000 South-Transdanubian Hungarian inhabitants. Clin. Exp. Rheumatol. 23, 801–808 (2005)PubMedGoogle Scholar
  3. 3.
    Villaverde-Hueso, A., Posada-De-la-Paz, M., Martin-Arribas, M.C., Sanchez-Valle, E., Ramirez-Gonzalez, A., Biairdi, P.: Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model. Pharmacoepidemiol. Drug Saf. 17, 1100–1107 (2008)CrossRefPubMedGoogle Scholar
  4. 4.
    Silman, A., Jannini, S., Symmons, D., Bacon, P.: An epidemiological study of scleroderma in the West Midlands. Br. J. Rheumatol. 27, 286–290 (1988)CrossRefPubMedGoogle Scholar
  5. 5.
    Arias-Nunez, M.C., Llorca, J., Vazquez-Rodriguez, T.R., Gomez-Acebo, I., Miranda-Filloy, J.A., Martin, J.: Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Med. (Baltimore). 87, 272–280 (2008)CrossRefGoogle Scholar
  6. 6.
    Haustein, U.F., Ziegler, V., Zschunke, E., et al.: Progressive systemic sclerosis with silicosis in the German Democratic Republic. In: Black, C.M., Myers, A.R. (eds.) Systemic sclerosis (scleroderma), pp. 138–142. Gower, New York (1985)Google Scholar
  7. 7.
    Monaco, A.L., Bruschi, M., Corte, R.L., et al.: Epidemiology of systemic sclerosis in a district of northern Italy. Clin. Exp. Rheumatol. 29(Suppl. 65), S10–S14 (2011)PubMedGoogle Scholar
  8. 8.
    Allcock, R.J., Forrest, I., Corris, P.A., Crook, P.R., Griffiths, I.D.: A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43, 596–602 (2004)CrossRefPubMedGoogle Scholar
  9. 9.
    Andréasson, K., Saxne, T., Bergknut, C., Hesselstrand, R., Englund, M.: Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann. Rheum. Dis. 73(10), 1788–1792 (2014)CrossRefPubMedGoogle Scholar
  10. 10.
    European Medicines Agency. Public summary of opinion on orphan designation. Committee for Orphan Medicinal Products. EMA/COMP/270/2003 Rev.2. 25 April 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005900.pdf (2014). Accessed 3 November 2015
  11. 11.
    Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., et al.: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47, 1185–1192 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chung, L., Domsic, R.T., Lingala, B., Alkassab, F., Bolster, M., Csuka, M.E., et al.: Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. (Hoboken) 66(3), 489–495 (2014)CrossRefGoogle Scholar
  13. 13.
    Schouffoer, A., Zirkzee, E., Henquet, S., Caljouw, M., Steup-Beekman, G., van Laar, J.: Vliet Vlieland, T.: Needs and preferences regarding health care delivery as perceived by patients with systemic sclerosis. Clin. Rheumatol. 30, 815–824 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    López-Bastida, J., Linertová, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P.: Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. (Hoboken) 66(3), 473–480 (2014)CrossRefGoogle Scholar
  15. 15.
    Hudson, M., Thombs, B.D., Steele, R., Panopalis, P., Newton, E., Baron, M.: Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum. 61, 1112–1120 (2009)CrossRefPubMedGoogle Scholar
  16. 16.
    Minier, T., Pentek, M., Brodszky, V., Ecseki, A., Karpati, K., Polgar, A., et al.: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49, 1920–1928 (2010)CrossRefGoogle Scholar
  17. 17.
    Bernatsky, S., Hudson, M., Panopalis, P., Clarke, A.E., Pope, J., LeClercq, S., et al, and the Canadian Scleroderma Research Group: The cost of systemic sclerosis. Arthritis Rheum. 61, 119–123 (2009)Google Scholar
  18. 18.
    Masserini, Belotti, Zeni, S., Cossutta, R., Soldi, A., Fantini, F.: Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients. Reumatismo 55, 245–255 (2003)Google Scholar
  19. 19.
    Wilson, L.: Cost-of-illness of scleroderma: the case for rare diseases. Semin. Arthritis Rheum. 27, 73–84 (1997)CrossRefPubMedGoogle Scholar
  20. 20.
    Strickland, G., Pauling, J., Cavill, C., McHugh, N.: Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin. Rheumatol. 31, 1215–1222 (2012)CrossRefPubMedGoogle Scholar
  21. 21.
    Gualtierotti, R., Scalone, L., Ingegnoli, F., Cortesi, P., Lubatti, C., Zeni, S., et al.: Health related quality of life assessment in patients with systemic sclerosis. Reumatismo 62, 210–214 (2010)PubMedGoogle Scholar
  22. 22.
    Hudson, M., Thombs, B.D., Steele, R., Panopalis, P., Newton, E., Baron, M.: The Canadian Scleroderma Research Group: quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. J. Rheumatol. 36, 768–772 (2009)CrossRefPubMedGoogle Scholar
  23. 23.
    Hudson, M., Steele, R., Taillefer, S., Baron, M.: The Canadian Scleroderma Research Group: quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 59, 270–278 (2008)CrossRefPubMedGoogle Scholar
  24. 24.
    Andrade, T.L., Camelier, A.A., Rosa, F.W., Santos, M.P., Jezler, S., Pereira e Silva, J.L.: Applicability of the 12-Item Short-Form health survey in patients with progressive systemic sclerosis. J Bras Pneumol. 33, 414–422 (2007)CrossRefPubMedGoogle Scholar
  25. 25.
    Khanna, D., Ahmed, M., Furst, D.E., Ginsburg, S.S., Park, G.S., Hornung, R., et al.: Health values of patients with systemic sclerosis. Arthritis Rheum. 57, 86–93 (2007)CrossRefPubMedGoogle Scholar
  26. 26.
    Rannou, F., Poiraudeau, S., Berezne, A., Baubet, T., Le-Guern, V., Cabane, J., et al.: Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36- Item Short Form Health Survey. Arthritis Rheum. 57, 94–102 (2007)CrossRefPubMedGoogle Scholar
  27. 27.
    Linertová, R., Serrano-Aguilar, P., Posada-de-la-Paz, M., Hens-Pérez, M., Kanavos, P., Taruscio, D., Schieppati, A., Stefanov, R., Péntek, M., Delgado, C., Graf von der Schulenburg, Persson, U., Chevreul, K., Fattore, G., Worbes-Cerezo, M., Sefton, M., López-Bastida, J., on behalf of BURQOL-RD Research Group: Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy 108(1), 19–26 (2012)CrossRefPubMedGoogle Scholar
  28. 28.
    Lopez-Bastida, J., Monton-Alvarez, F., Serrano-Aguilar, P., Perestelo-Perez, L.: The social-economic costs in patients with ataxias cerebelosas in Spain. Mov. Disord. 23, 212–217 (2008)CrossRefPubMedGoogle Scholar
  29. 29.
    Lopez-Bastida, J., Perestelo-Perez, L., Monton-Alvarez, F., Serrano-Aguilar, P., Alfonso-Sanchez, J.L.: Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 26, 1–7 (2008)Google Scholar
  30. 30.
    Brooks, R.: EuroQol: the current state of play. Health Policy 37, 53–72 (1996)CrossRefPubMedGoogle Scholar
  31. 31.
    Lopez-Bastida, J., Oliva, J., Perestelo-Perez, L., Serrano-Aguilar, P.: The economic costs and health-related quality of life of people with HIV and AIDS in the Canary Islands. Spain. BMC Health Serv Res. 9, 55–62 (2009)CrossRefPubMedGoogle Scholar
  32. 32.
    McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–405 (2001)CrossRefPubMedGoogle Scholar
  33. 33.
    Van den Berg, B., Brouwer, W., Koopmanschap, M.: Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ. 5, 36–45 (2004)CrossRefPubMedGoogle Scholar
  34. 34.
    Hodgson, T.A., Meiners, M.R.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Mem Fund Q. 60, 429–491 (1982)CrossRefGoogle Scholar
  35. 35.
    Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)Google Scholar
  36. 36.
    Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)CrossRefPubMedGoogle Scholar
  37. 37.
    Mahoney, F.I., Barthel, D.W.: Functional evaluation: the Barthel Index. Md State Med 14, 61–65 (1965)Google Scholar
  38. 38.
    Shah, S., Vanclay, F., Cooper, B.: Improving the sensitivity of the Barthel Index for stroke rehabilitation. J. Clin. Epidemiol. 42, 703–709 (1989)CrossRefPubMedGoogle Scholar
  39. 39.
    Ruzafa, Cid: J., Damian Moreno, J.: Valoracion de la discapacidad fisica: el Indice de Barthel. Rev Esp Salud Publica. 71, 127–137 (1997)CrossRefGoogle Scholar
  40. 40.
    Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging. 494–507 (2000)Google Scholar
  41. 41.
    Szende, A., Janssen, B., Cabases, J. (eds.).: Self-Reported Population Health: An International Perspective based on EQ-5D. Springer, Netherlands (2014)Google Scholar
  42. 42.
    Oliva, J., López-Bastida, J., Montejo, A.L., Osuna, R., Duque, B.: The socioeconomic costs of mental illness in Spain. Eur. J. Health Econ. 10, 361–369 (2009)CrossRefGoogle Scholar
  43. 43.
    Angelis, A., Tordrup, D., Kanavos, P.: Socio-Economic Burden of Rare Diseases: A Systematic Review of Cost of Illness Evidence. Health Policy 119(7), 964–979 (2015)CrossRefPubMedGoogle Scholar
  44. 44.
    Villaverde-Hueso, A., Sanchez-Valle, E., Alvarez, E., Morant, C., Carreira, P.E., Martin-Arribas, M.C., et al.: Estimating the burden of scleroderma disease in Spain. J. Rheumatol. 34, 2236–2242 (2007)PubMedGoogle Scholar
  45. 45.
    Ghatnekar, O., Glenngard, A.H., Olofsson, S., Persson, U.: A literature review of instruments for measuring health-related quality of life in rare diseases: internal report of BURQOL-RD. The Swedish Institute for Health Economics. (2011)Google Scholar
  46. 46.
    Furst, D., Khanna, D., Matucci-Cerinic, M., Clements, P., Steen, V., Pope, J., et al.: Systemic sclerosis: continuing progress in developing clinical measures of response. J. Rheumatol. 34, 1194–1200 (2007)PubMedGoogle Scholar
  47. 47.
    Hu, T.W.: Perspectives: an international review of the national cost estimates of mental illness, 1990–2003. J. Ment. Health Policy Econ. 9, 3–13 (2006)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Julio López-Bastida
    • 1
    • 2
    Email author
  • Renata Linertová
    • 2
    • 3
  • Juan Oliva-Moreno
    • 2
    • 4
  • Pedro Serrano-Aguilar
    • 2
    • 5
  • Manuel Posada-de-la-Paz
    • 6
  • Panos Kanavos
    • 7
  • Domenica Taruscio
    • 8
  • Arrigo Schieppati
    • 9
  • Georgi Iskrov
    • 10
    • 11
  • Márta Péntek
    • 12
  • Claudia Delgado
    • 13
  • Johann Mathias von der Schulenburg
    • 14
  • Ulf Persson
    • 15
  • Karine Chevreul
    • 16
    • 17
    • 18
  • Giovanni Fattore
    • 19
  • The BURQOL-RD Research Network
  1. 1.Universidad de Castilla-La ManchaToledoSpain
  2. 2.Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC)MadridSpain
  3. 3.Fundación Canaria de Investigación Sanitaria (FUNCANIS)Las Palmas de Gran CanariaSpain
  4. 4.Universidad de Castilla-La ManchaToledoSpain
  5. 5.Evaluation and Planning Service at Canary Islands Health ServiceSanta Cruz de TenerifeSpain
  6. 6.Instituto de Investigación en Enfermedades Raras (IIER)SpainRDR and CIBERERMadridSpain
  7. 7.Health and Social Care Research CentreLondon School of Economics and Political ScienceLondonUK
  8. 8.National Center for Rare DiseasesIstituto Superiore di Sanità (ISS)RomeItaly
  9. 9.Centro di Ricerche Cliniche per Malattie Rare Aldo e Cele DaccòIstituto di Ricerche Farmacologiche Mario NegriRanica (Bergamo)Italy
  10. 10.Institute of Rare DiseasesPlovdivBulgaria
  11. 11.Department of Social Medicine and Public Health, Faculty of Public HealthMedical University of PlovdivPlovdivBulgaria
  12. 12.Department of Health EconomicsCorvinus University of BudapestBudapestHungary
  13. 13.Federación Española de Enfermedades Raras (FEDER)MadridSpain
  14. 14.Centre for Health Economics Research Hannover (CHERH)/Institute for Risk and InsuranceLeibniz Universität HannoverHannoverGermany
  15. 15.Swedish Institute for Health EconomicsLundSweden
  16. 16.URC Eco Ile de France, AP-HPParisFrance
  17. 17.Université Paris Diderot Sorbonne Paris Cité, ECEVE, UMRS 1123ParisFrance
  18. 18.INSERM, ECEVE, U1123ParisFrance
  19. 19.Centre for Research on Health and Social Care Management (CERGAS)Bocconi UniversityMilanItaly

Personalised recommendations